Fosun International Ltd boosted its position in shares of Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by 9.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 710,000 shares of the company’s stock after buying an additional 60,000 shares during the period. Dova Pharmaceuticals accounts for approximately 1.7% of Fosun International Ltd’s portfolio, making the stock its 18th biggest holding. Fosun International Ltd owned about 2.77% of Dova Pharmaceuticals worth $17,239,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DOVA. FMR LLC acquired a new position in Dova Pharmaceuticals during the second quarter worth approximately $43,969,000. Paulson & CO. Inc. acquired a new position in Dova Pharmaceuticals during the second quarter worth approximately $13,856,000. Wells Fargo & Company MN acquired a new position in Dova Pharmaceuticals during the second quarter worth approximately $4,458,000. Nexthera Capital LP acquired a new position in Dova Pharmaceuticals during the second quarter worth approximately $4,415,000. Finally, Sphera Funds Management LTD. acquired a new position in Dova Pharmaceuticals during the second quarter worth approximately $2,118,000. 26.20% of the stock is currently owned by institutional investors.
Several research analysts have weighed in on DOVA shares. Leerink Swann upgraded Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price on the stock in a research note on Tuesday, September 26th. Jefferies Group lifted their target price on Dova Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research note on Tuesday, November 28th. Finally, Zacks Investment Research downgraded Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th.
Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) opened at $29.44 on Wednesday. Dova Pharmaceuticals, Inc. has a 12 month low of $16.98 and a 12 month high of $30.48.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.08). During the same quarter in the prior year, the firm posted ($0.41) earnings per share. analysts expect that Dova Pharmaceuticals, Inc. will post -1.51 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Dova Pharmaceuticals, Inc. (DOVA) Shares Bought by Fosun International Ltd” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/12/06/dova-pharmaceuticals-inc-dova-shares-bought-by-fosun-international-ltd.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals, Inc. (NASDAQ:DOVA).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.